Eli Lilly Raises Sales Guidance Again as Zepbound Fuels Record Stock
Eli Lilly lifted its annual sales forecast for the third time in 2024 after Zepbound weight-loss drug revenues surged, pushing shares to an all-time high.
Eli Lilly raised its full-year sales guidance for the third time in 2024 after blockbuster demand for its Zepbound weight-loss injection drove revenues sharply higher, sending the drugmaker's stock to a record closing price, the company announced Wednesday.
Zepbound has become a cornerstone of Lilly's growth story, cementing the Indianapolis-based pharmaceutical giant's dominance in the U.S. prescription weight-loss drug market — a category that has exploded in size as millions of Americans seek GLP-1-based obesity treatments. The repeated upward revisions to guidance signal that demand continues to outpace even management's own bullish projections.
Read more Why Marvell Investors Are Alarmed Over Lumentum Deal Rumors →
The three guidance increases in a single calendar year underscore just how rapidly the obesity-drug landscape has shifted. Lilly and rival Novo Nordisk have together reshaped expectations for the pharmaceutical sector, but Lilly's repeated forecast hikes suggest it is capturing an outsized share of new prescriptions and market momentum in the United States.
For investors, a record-high close reflects growing conviction that weight-loss drugs represent a durable, multi-year revenue stream rather than a fleeting trend. Analysts broadly expect the GLP-1 market to expand into additional therapeutic indications, potentially widening Lilly's addressable opportunity well beyond obesity alone.
Continue reading at MarketWatch.com
